MA53172A - Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 - Google Patents

Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1

Info

Publication number
MA53172A
MA53172A MA053172A MA53172A MA53172A MA 53172 A MA53172 A MA 53172A MA 053172 A MA053172 A MA 053172A MA 53172 A MA53172 A MA 53172A MA 53172 A MA53172 A MA 53172A
Authority
MA
Morocco
Prior art keywords
interleukin
activity inhibitors
sulfonimidamide
compounds
sulfonimidamide compounds
Prior art date
Application number
MA053172A
Other languages
English (en)
Inventor
Amogh Boloor
Sarah M Bronner
Christopher Mcbride
Richard M Pastor
Nadezda Sokolova
Steven Thomas Staben
Craig Stivala
Lynnie Lin Trzoss
Matthew Volgraf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA53172A publication Critical patent/MA53172A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA053172A 2018-07-20 2019-07-19 Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 MA53172A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862701313P 2018-07-20 2018-07-20

Publications (1)

Publication Number Publication Date
MA53172A true MA53172A (fr) 2021-05-26

Family

ID=67659954

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053172A MA53172A (fr) 2018-07-20 2019-07-19 Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1

Country Status (21)

Country Link
US (2) US12234245B2 (fr)
EP (1) EP3823974A1 (fr)
JP (1) JP7320595B2 (fr)
KR (1) KR20210034596A (fr)
CN (1) CN112513048A (fr)
AR (1) AR115822A1 (fr)
AU (1) AU2019306658A1 (fr)
BR (1) BR112021001044A2 (fr)
CA (1) CA3105521A1 (fr)
CL (1) CL2021000153A1 (fr)
CO (1) CO2021001530A2 (fr)
CR (1) CR20210022A (fr)
IL (1) IL279256A (fr)
MA (1) MA53172A (fr)
MX (1) MX2021000780A (fr)
PE (1) PE20211811A1 (fr)
PH (1) PH12021500005A1 (fr)
SG (1) SG11202013062VA (fr)
TW (1) TWI825134B (fr)
UA (1) UA128558C2 (fr)
WO (1) WO2020018975A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7163293B2 (ja) 2017-01-23 2022-10-31 ジェネンテック， インコーポレイテッド インターロイキン－１活性の阻害剤としての化学化合物
CN117209447A (zh) 2017-07-24 2023-12-12 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
WO2019068772A1 (fr) 2017-10-03 2019-04-11 Inflazome Limited Nouveaux composés
PE20211811A1 (es) 2018-07-20 2021-09-14 Hoffmann La Roche Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
CA3104199A1 (fr) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Composes de sulfonyluree en tant qu'inhibiteurs de l'activite de l'interleukine 1
CN120531732A (zh) * 2018-11-13 2025-08-26 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US12134611B2 (en) 2018-11-13 2024-11-05 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
ES2974842T3 (es) 2018-11-13 2024-07-01 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de nlrp
US20230051589A1 (en) * 2018-11-16 2023-02-16 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
WO2020154499A1 (fr) * 2019-01-23 2020-07-30 Novartis Inflammasome Research, Inc. Composés sulfonimidamide et compositions pour le traitement d'états associés à une activité de nlrp
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
WO2021002887A1 (fr) * 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie
CA3151865A1 (fr) 2019-07-17 2021-01-21 Zomagen Biosciences Ltd Derives de n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-4,5,6,7-tetrahydrobenzofuran -2-sulfonamide et composes apparentes en tant que modulateurs de nlpr3 pour le traiteme nt de la sclerose en plaques (sep)
JP7595642B2 (ja) 2019-07-17 2024-12-06 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
JP7392169B2 (ja) * 2019-11-12 2023-12-05 成都百裕制薬股▲ふん▼有限公司 アミド誘導体及びその調製方法並びに医薬における応用
WO2021150574A1 (fr) * 2020-01-22 2021-07-29 Genentech, Inc. Composés de sulfonimidamide en tant que modulateurs de nlrp3
JP2023518044A (ja) * 2020-03-16 2023-04-27 ズーマゲン バイオサイエンシーズ エルティーディー Ｎｌｒｐ３モジュレーター
CA3174837A1 (fr) 2020-04-15 2021-10-21 Daniel Oehlrich Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides utilises comme inhibiteurs de la voie de l'inflammasome nlrp3
MX2022012896A (es) 2020-04-15 2022-11-09 Janssen Pharmaceutica Nv Pirrolo[1,2-d][1,2,4]triazin-2-ilacetamidas como inhibidores de la ruta del inflamasoma nlrp3.
US20230203064A1 (en) 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3
KR20230005320A (ko) * 2020-04-30 2023-01-09 얀센 파마슈티카 엔.브이. 신규 트리아지노인돌 화합물
AU2021279305A1 (en) 2020-05-28 2023-02-09 Janssen Pharmaceutica Nv Compounds
CA3178361A1 (fr) 2020-06-19 2021-12-23 Emanuele Gabellieri Derives de dihydrooxazole et de thiouree modulant la voie inflammatoire nlrp3
EP3974415A1 (fr) 2020-09-24 2022-03-30 Janssen Pharmaceutica NV Nouveaux composés
CA3189887A1 (fr) 2020-09-24 2022-03-31 Daniel Oehlrich Nouveaux composes
CN114539256B (zh) * 2020-11-20 2024-02-02 上海拓界生物医药科技有限公司 三环化合物及其医药用途
MX2023010223A (es) 2021-03-04 2023-09-11 Janssen Pharmaceutica Nv Derivados de 4-amino-6-oxo-piridazina que modulan la nlrp3.
WO2022184842A1 (fr) 2021-03-04 2022-09-09 Janssen Pharmaceutica Nv Dérivés de 4-alcoxy-6-oxo-pyridazine modulant nlrp3
CA3212725A1 (fr) 2021-04-29 2022-11-03 Daniel Oehlrich Derives de phtalazinone en tant qu'inhibiteurs d'inflammation de nlrp3
WO2022237782A1 (fr) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 Dérivé d'amide et son application
WO2022237781A1 (fr) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 Dérivé d'amide et son application
WO2023275230A1 (fr) 2021-07-01 2023-01-05 Janssen Pharmaceutica Nv Acétamides 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl
EP4373826A1 (fr) * 2021-07-19 2024-05-29 Genentech, Inc. Composés de sulfonimidamde et leurs utilisations
CN115894478B (zh) * 2021-09-30 2025-04-04 杭州民生药物研究院有限公司 一种新型吡啶并吡唑类杂环化合物及其应用
US20250109126A1 (en) 2021-12-22 2025-04-03 Ac Immune Sa Dihydro-oxazol derivative compounds
CN116804018A (zh) * 2022-03-25 2023-09-26 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
CN117247393A (zh) * 2022-06-17 2023-12-19 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
WO2024010772A1 (fr) * 2022-07-06 2024-01-11 Kodiak Sciences Inc. Inhibiteurs de nlrp3
JP2025524640A (ja) 2022-07-14 2025-07-30 エーシー・イミューン・エス・アー Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体
CN119998284A (zh) 2022-07-28 2025-05-13 Ac免疫有限公司 新化合物
IL319619A (en) 2022-09-23 2025-05-01 Merck Sharp & Dohme Llc Phthalazine derivatives used as NOD-LIKE PROTEIN 3 receptor inhibitors
WO2024249539A1 (fr) 2023-06-02 2024-12-05 Merck Sharp & Dohme Llc Hétérocyles bicycliques insaturés 5,6 utiles comme inhibiteurs de la protéine réceptrice de type nod 3
WO2025101716A1 (fr) * 2023-11-07 2025-05-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Procédés de synthèse de composés de soufre (vi) trifonctionnalisé
TW202535370A (zh) 2023-12-14 2025-09-16 美商默沙東有限責任公司 作為nod樣受體蛋白3抑制劑之吲唑衍生物
US20250223290A1 (en) 2023-12-14 2025-07-10 Merck Sharp & Dohme Llc Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3
WO2025133307A1 (fr) 2023-12-22 2025-06-26 Ac Immune Sa Modulateurs hétérocycliques de la voie de l'inflammasome nlrp3
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法
WO2025153624A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025153625A1 (fr) 2024-01-17 2025-07-24 Ac Immune Sa Dérivés d'imidazo[1,2-d][1,2,4]triazine destinés à être utilisés en tant qu'inhibiteurs de la voie de l'inflammasome nlrp3
WO2025163069A1 (fr) 2024-01-31 2025-08-07 Ac Immune Sa Nouveaux composés
US20250326772A1 (en) 2024-04-19 2025-10-23 Kyorin Pharmaceutical Co., Ltd. Mrgprx2 antagonists, pharmaceutical composition including mrgprx2 antagonist, and method of treating mrgprx2-mediated disease or disorder
CN119100956B (zh) * 2024-09-03 2025-12-02 大连理工大学 一种无催化剂的光驱动合成亚磺酰胺类化合物的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705555A (en) * 1984-08-08 1987-11-10 E. I. Du Pont De Nemours And Company Herbicidal triazines
US5216026A (en) 1990-07-17 1993-06-01 Eli Lilly And Company Antitumor compositions and methods of treatment
DE19540995A1 (de) 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
BR9714328A (pt) 1997-01-29 2000-03-21 Pfizer da atividade de interleucina-1
CA2383026A1 (fr) 1999-09-14 2001-03-22 Pfizer Products Inc. Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
WO2003045400A1 (fr) 2001-11-30 2003-06-05 Pfizer Products Inc. Combinaison d'un inhibiteur d'il-1/18 avec un inhibiteur de tnf pour le traitement d'inflammations
MX341482B (es) 2010-02-22 2016-08-22 Raqualia Pharma Inc Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
US20140221340A1 (en) 2011-09-02 2014-08-07 Kyowa Hakko Kirin Co., Ltd. Chemokine receptor activity regulator
WO2014190015A1 (fr) 2013-05-21 2014-11-27 Virginia Commonwealth University Inhibiteurs de cryopyrines pour prévenir et traiter l'inflammation
MY193765A (en) * 2015-02-16 2022-10-27 Univ Queensland Sulfonylureas and related compounds and use of same
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11858922B2 (en) 2016-02-16 2024-01-02 The University Of Queensland Sulfonylureas and related compounds and use of same
US11447460B2 (en) 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
JP7050751B2 (ja) 2016-04-18 2022-04-08 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物
JP7163293B2 (ja) 2017-01-23 2022-10-31 ジェネンテック， インコーポレイテッド インターロイキン－１活性の阻害剤としての化学化合物
US11840543B2 (en) 2017-05-24 2023-12-12 The University Of Queensland Compounds and uses
US11236045B2 (en) 2017-06-09 2022-02-01 Cadila Healthcare Limited Substituted sulfoximine compounds
HRP20220195T1 (hr) 2017-07-07 2022-04-15 Inflazome Limited Novi spojevi sulfonamid karboksamida
WO2019008029A1 (fr) 2017-07-07 2019-01-10 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
CN117209447A (zh) * 2017-07-24 2023-12-12 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
CN111132974B (zh) 2017-08-15 2023-11-21 英夫拉索姆有限公司 新颖的磺酰胺羧酰胺化合物
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
EP3668601A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
PE20200758A1 (es) 2017-08-15 2020-07-27 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
EP3668862A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
EP3668843A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylurées et sulfonylthiourées utilisés en tant qu'inhibiteurs de nlrp3
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
WO2019068772A1 (fr) * 2017-10-03 2019-04-11 Inflazome Limited Nouveaux composés
WO2019092172A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
CA3078195A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composes de sulfonamide carboxamide
WO2019092171A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
GB201803394D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
GB201803393D0 (en) 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
GB201806578D0 (en) 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
CA3103664A1 (fr) 2018-07-03 2020-01-09 Novartis Ag Methodes de traitement ou de selection d'un traitement pour un sujet resistant a un inhibiteur de tnf a l'aide d'un antagoniste de nlrp3
JP2021529187A (ja) 2018-07-03 2021-10-28 ノバルティス アーゲー Ｎｌｒｐモジュレータ
PE20211811A1 (es) 2018-07-20 2021-09-14 Hoffmann La Roche Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1
US10981918B2 (en) 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives
CA3104199A1 (fr) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Composes de sulfonyluree en tant qu'inhibiteurs de l'activite de l'interleukine 1
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
PE20211333A1 (es) 2018-08-15 2021-07-22 Inflazome Ltd Compuestos de sulfonamidaurea novedosos
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
JP2022505525A (ja) 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
US12134611B2 (en) 2018-11-13 2024-11-05 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
CN120531732A (zh) 2018-11-13 2025-08-26 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US20230051589A1 (en) 2018-11-16 2023-02-16 Novartis Ag Compounds and compositions for treating conditions associated with nlrp activity
GB201819083D0 (en) 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020154321A1 (fr) 2019-01-22 2020-07-30 Novartis Inflammasome Research, Inc. Composés et compositions pour traiter des états associés à une activité de nlrp
WO2020154499A1 (fr) 2019-01-23 2020-07-30 Novartis Inflammasome Research, Inc. Composés sulfonimidamide et compositions pour le traitement d'états associés à une activité de nlrp
CN118221763A (zh) 2019-03-29 2024-06-21 免疫医疗有限公司 化合物及其缀合物
US20220378801A1 (en) 2019-06-21 2022-12-01 Ac Immune Sa Novel compounds
WO2021002887A1 (fr) 2019-07-02 2021-01-07 Novartis Inflammasome Research, Inc. Antagonistes de nlrp3 ciblant l'intestin et leur utilisation en thérapie
EP4077326A4 (fr) 2019-12-19 2024-04-24 Jacobio Pharmaceuticals Co., Ltd. Inhibiteurs de protéine mutante kras
AR121078A1 (es) 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
TWI785474B (zh) 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
WO2021150574A1 (fr) 2020-01-22 2021-07-29 Genentech, Inc. Composés de sulfonimidamide en tant que modulateurs de nlrp3
JP7736313B2 (ja) 2020-01-29 2025-09-09 ウニバシタット デ レス イレス バレアース αヒドロキシル化脂肪酸代謝産物、その医学的使用およびバイオマーカーとしての使用
US20230203064A1 (en) 2020-04-23 2023-06-29 Janssen Pharmaceutica Nv Tricyclic compounds as inhibitors of nlrp3
KR20230005320A (ko) 2020-04-30 2023-01-09 얀센 파마슈티카 엔.브이. 신규 트리아지노인돌 화합물
WO2021234608A1 (fr) 2020-05-19 2021-11-25 Cybin Irl Limited Dérivés de tryptamine deutérés et procédés d'utilisation
AU2021279305A1 (en) 2020-05-28 2023-02-09 Janssen Pharmaceutica Nv Compounds
CA3178361A1 (fr) 2020-06-19 2021-12-23 Emanuele Gabellieri Derives de dihydrooxazole et de thiouree modulant la voie inflammatoire nlrp3
IL277528B (en) 2020-09-22 2022-05-01 Ag Plenus Ltd Herbicidal compounds and methods of their use
CA3189887A1 (fr) 2020-09-24 2022-03-31 Daniel Oehlrich Nouveaux composes
WO2022184842A1 (fr) 2021-03-04 2022-09-09 Janssen Pharmaceutica Nv Dérivés de 4-alcoxy-6-oxo-pyridazine modulant nlrp3
CA3212725A1 (fr) 2021-04-29 2022-11-03 Daniel Oehlrich Derives de phtalazinone en tant qu'inhibiteurs d'inflammation de nlrp3
WO2022237781A1 (fr) 2021-05-10 2022-11-17 成都百裕制药股份有限公司 Dérivé d'amide et son application
WO2023275230A1 (fr) 2021-07-01 2023-01-05 Janssen Pharmaceutica Nv Acétamides 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl

Also Published As

Publication number Publication date
PH12021500005A1 (en) 2021-09-13
MX2021000780A (es) 2021-03-31
IL279256A (en) 2021-01-31
CR20210022A (es) 2021-02-18
KR20210034596A (ko) 2021-03-30
CA3105521A1 (fr) 2020-01-23
US20210253596A1 (en) 2021-08-19
SG11202013062VA (en) 2021-02-25
JP7320595B2 (ja) 2023-08-03
AU2019306658A1 (en) 2021-01-07
TW202016078A (zh) 2020-05-01
PE20211811A1 (es) 2021-09-14
CN112513048A (zh) 2021-03-16
CL2021000153A1 (es) 2021-07-09
UA128558C2 (uk) 2024-08-14
BR112021001044A2 (pt) 2021-04-13
JP2021532101A (ja) 2021-11-25
US20250115618A1 (en) 2025-04-10
CO2021001530A2 (es) 2021-03-08
WO2020018975A1 (fr) 2020-01-23
EP3823974A1 (fr) 2021-05-26
US12234245B2 (en) 2025-02-25
AR115822A1 (es) 2021-03-03
TWI825134B (zh) 2023-12-11

Similar Documents

Publication Publication Date Title
MA53172A (fr) Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
MA53170A (fr) Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1
EP3941898C0 (fr) Composés fongicides
EP3827009A4 (fr) Composés hétérobicycliques pour inhiber l'activité de shp2
EP3740487A4 (fr) Composés benzamide
EP3956033A4 (fr) Composés bicycliques
MA55695A (fr) Composés chimiques comme inhibiteurs de l'activité interleukine-1
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
EP3836923A4 (fr) Composés pyrrolo-dipyridine
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA52948A (fr) Composés
IL289767A (en) Novel heteroaryl-triazole compounds as pesticides
MA49566A (fr) Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
MA51669A (fr) Composés
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
MA52942A (fr) Composés inhibiteurs d'oga
MA51438A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA53003A (fr) Composés
EP3852745A4 (fr) Composés destinés au traitement de certaines leucémies
MA49374A (fr) Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine
IL280598A (en) 2,6-diamino pyridine compounds
EP3678700A4 (fr) Composés pour la réduction de la viscosité de formulations biologiques
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants